Two BRM promoter polymorphisms predict poor survival in patients with hepatocellular carcinoma

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Molecular Carcinogenesis

• Publication date

  2018-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/mc.22736PMID 28892201
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Association of BRM promoter polymorphisms and esophageal adenocarcinoma outcome

  2017cited by this paper
• Hepatocellular carcinoma in elderly patients: challenges and solutions

  2016cited by this paper
• BRM polymorphisms, pancreatic cancer risk and survival

  2016cited by this paper
• Mechanism of BRG1 silencing in primary cancers

  2016cited by this paper
• Loss of the SWI/SNF ATPase subunits BRM and BRG1 drives lung cancer development

  2016cited by this paper
• BRM Promoter Polymorphisms and Survival of Advanced Non–Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial

  2016cited by this paper
• BRG1 and BRM loss selectively impacts RB and P53, respectively: BRG1 and BRM have differential functions in vivo

  2016cited by this paper
• Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics

  2015cited by this paper
• ADNP: in search for molecular mechanisms and innovative therapeutic strategies for frontotemporal degeneration

  2015cited by this paper
• Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study

  2015influential reference
• Two BRM promoter insertion polymorphisms increase the risk of early-stage upper aerodigestive tract cancers

  2014cited by this paper
• SWI/SNF chromatin-remodeling complexes in cardiovascular development and disease.

  2014cited by this paper
• Identifying targets for the restoration and reactivation of BRM

  2014cited by this paper
• The silencing of the SWI/SNF subunit and anticancer gene BRM in Rhabdoid tumors

  2014cited by this paper
• Flavonoids from each of the six structural groups reactivate BRM, a possible cofactor for the anticancer effects of flavonoids.

  2014cited by this paper
• Association of two BRM promoter polymorphisms with head and neck squamous cell carcinoma risk.

  2013cited by this paper
• The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium

  2013cited by this paper
• Insertion/Deletion Polymorphisms in the Promoter Region of BRM Contribute to Risk of Hepatocellular Carcinoma in Chinese Populations

  2013cited by this paper
• Hepatocellular carcinoma

  2012cited by this paper
• SWI/SNF nucleosome remodellers and cancer

  2011cited by this paper
• A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma.

  2011cited by this paper
• Pharmacologic reversal of epigenetic silencing of the anticancer protein BRM: a novel targeted treatment strategy

  2011cited by this paper
• Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung cancer risk

  2011cited by this paper
• Discovery of BRM Targeted Therapies: Novel Reactivation of an Anti-cancer Gene.

  2011cited by this paper
• Decreased expression of GRAF1/OPHN-1-L in the X-linked alpha thalassemia mental retardation syndrome

  2010cited by this paper
• SWI/SNF has intrinsic nucleosome disassembly activity that is dependent on adjacent nucleosomes.

  2010cited by this paper
• Schimke immunoosseous dysplasia: defining skeletal features

  2009cited by this paper
• The SWI/SNF complex and cancer

  2009cited by this paper
• SWI/SNF Mediates Polycomb Eviction and Epigenetic Reprogramming of the INK4b-ARF-INK4a Locus

  2008cited by this paper
• Characterization of mammary tumors from Brg1 heterozygous mice

  2008cited by this paper
• The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer.

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis.

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Frequent loss of Brm expression in gastric cancer correlates with histologic features and differentiation state.

  2007cited by this paper
• The reversible epigenetic silencing of BRM: implications for clinical targeted therapy

  2007cited by this paper
• The Brm gene suppressed at the post-transcriptional level in various human cell lines is inducible by transient HDAC inhibitor treatment, which exhibits antioncogenic potential

  2005cited by this paper
• Reconstitution of Glucocorticoid Receptor-Dependent Transcription In Vivo

  2004cited by this paper
• Chromatin Remodeling Factors and BRM/BRG1 Expression as Prognostic Indicators in Non-Small Cell Lung Cancer

  2004influential reference
• Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

  2003cited by this paper
• Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis.

  2003cited by this paper
• Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies

  2001cited by this paper
• The BRG-1 Subunit of the SWI/SNF Complex Regulates CD44 Expression*

  2001cited by this paper
• Reconstitution of a core chromatin remodeling complex from SWI/SNF subunits.

  1999cited by this paper
• c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function

  1999cited by this paper
• RB and hbrm cooperate to repress the activation functions of E2F1.

  1997cited by this paper
• Purification and biochemical heterogeneity of the mammalian SWI‐SNF complex.

  1996cited by this paper
• Hepatocellular carcinoma.

  1986cited by this paper

• Genetic Polymorphisms in CD35 Gene Contribute to the Susceptibility and Prognosis of Hepatocellular Carcinoma

  2021cites this paper
• WSB1 and IL21R Genetic Variants Are Involved in Th2 Immune Responses to Ascaris lumbricoides

  2021cites this paper
• HELLS serves as a poor prognostic biomarker and its downregulation reserves the malignant phenotype in pancreatic cancer

  2021cites this paper
• A genetic variant in the promoter of CD46 is associated with the risk and prognosis of hepatocellular carcinoma

  2020cites this paper
• Association of two BRM promoter polymorphisms and smoking status with malignant pleural mesothelioma risk and prognosis

  2019cites this paper
• Recurrent chromosomal and epigenetic alterations in oral squamous cell carcinoma and its putative premalignant condition oral lichen planus

  2019cites this paper
• BRM: the core ATPase subunit of SWI/SNF chromatin-remodelling complex—a tumour suppressor or tumour-promoting factor?

  2019cites this paper
• Brahma deficiency in keratinocytes promotes UV carcinogenesis by accelerating the escape from cell cycle arrest and the formation of DNA photolesions.

  2018cites this paper
• Two functional indel polymorphisms in the promoter region of the Brahma gene (BRM) and disease risk and progression-free survival in colorectal cancer

  2018cites this paper
• The association of lncRNA-HULC polymorphisms with hepatocellular cancer risk and prognosis.

  2018cites this paper